Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorobenzene SCHEMBL7193680 | 0.96 | MEN1 (0.53) | MEN1KMT2AEPHX1HDAC3HDAC4 | |
| SCHEMBL4480606 | 0.92 | HDAC3 (0.57) | MEN1KMT2AEPHX1HDAC3HDAC4 | |
| SCHEMBL741751 | 0.87 | MEN1 (0.58) | MEN1KMT2AEPHX1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL8550499 | 0.85 | MEN1 (0.56) | MEN1KMT2AEPHX1HDAC3HDAC4 | |
| SCHEMBL3985471 | 0.83 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL27545340 | 0.83 | HDAC3 (0.53) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28038711 | 0.82 | KMT2A (0.54) | MEN1KMT2AEPHX1HDAC3HDAC4 | |
| Acetic Acid SCHEMBL9853044 | 0.81 | MEN1 (0.53) | MEN1KMT2AEPHX1HDAC3HDAC4 | |
| SCHEMBL28807102 | 0.80 | MEN1 (0.53) | MEN1KMT2AEPHX1HDAC3HDAC4 | |
| SCHEMBL7758852 | 0.80 | MEN1 (0.77) | MEN1KMT2AEPHX1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943138-A | Compositions comprising GARDOS channel antagonists and uses thereof | 阿迪玛生物有限责任公司 | 2023-04-07 | — | — | CN | claimed |
| CN-112020353-A | Crystal form A of 2, 2-bis (4-fluorophenyl) -2-phenylacetamide and preparation method and application thereof | 深圳仁泰医药科技有限公司 | 2020-12-01 | — | — | CN | claimed |
| CN-105246891-A | Novel compounds for the treatment of cancer | Bayer Pharma AG | 2016-01-13 | — | — | CN | claimed |
| CN-115943138-A | Compositions comprising GARDOS channel antagonists and uses thereof | 阿迪玛生物有限责任公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115943138-A | Compositions comprising GARDOS channel antagonists and uses thereof | 阿迪玛生物有限责任公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-112020489-B | Crystal form A of 2- (2, 5-dioxopyrrolidine-1-yl) ethyl methyl fumarate and preparation method and application thereof | 深圳仁泰医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-112020353-A | Crystal form A of 2, 2-bis (4-fluorophenyl) -2-phenylacetamide and preparation method and application thereof | 深圳仁泰医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-112020353-A | Crystal form A of 2, 2-bis (4-fluorophenyl) -2-phenylacetamide and preparation method and application thereof | 深圳仁泰医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-112020489-A | Crystal form A of 2- (2, 5-dioxopyrrolidine-1-yl) ethyl methyl fumarate and preparation method and application thereof | 深圳仁泰医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-112020353-A | Crystal form A of 2, 2-bis (4-fluorophenyl) -2-phenylacetamide and preparation method and application thereof | 深圳仁泰医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-105246891-A | Novel compounds for the treatment of cancer | Bayer Pharma AG | 2016-01-13 | — | — | CN | disclosed |
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| CN-101437403-A | Treatment methods using triaryl methane compounds | ICAGEN INC (US) | 2009-05-20 | — | — | CN | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| CN-1193748-C | Gardos channel antagonists | ICAGEN INC (US) | 2005-03-23 | — | — | CN | disclosed |
| CN-1344158-A | Gardos channel antagonists | ICAGEN INC (US) | 2002-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | MEN1 4657/4885KMT2A 3881/4885EPHX1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.